Brief: Mirati Therapeutics Announces Departure Of Chief Executive Officer David Meek
08/08/2023 22:19
Aug 8 (Reuters) - Mirati Therapeutics Inc MRTX.O :
* MIRATI THERAPEUTICS ANNOUNCES DEPARTURE OF CHIEF EXECUTIVE
OFFICER DAVID MEEK
* MIRATI THERAPEUTICS INC - CHARLES M. BAUM, M.D., PH.D.
ASSUMES
ROLE OF INTERIM CEO
* MIRATI THERAPEUTICS INC - CHARLES M. BAUM, M.D., PH.D.
ASSUMES
ROLE OF INTERIM CEO
* MIRATI THERAPEUTICS INC - MEEK WILL REMAIN AS A CONSULTANT
TO
COMPANY THROUGH OCTOBER 15, 2023
Source text for Eikon: ID:nPncv8dBa
Further company coverage: MRTX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Mirati Therapeutics
See all newsBrief: European Commission Approves KRAZATI As A Targeted Treatment For Non-Small Cell Lung Cancer
US FDA turns down Amgen lung cancer drug Lumakras for full approval (updated)
US FDA turns down Amgen lung cancer drug Lumakras for full approval
Brief: Mirati Stockholders Voted 'For' Proposal To Adopt Deal Between Co, Bristol-Myers Squibb
Mirati's lung cancer drug gets EU's regulatory backing (updated)